BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 37806507)

  • 1. Aptamer-modified chitosan-capped mesoporous silica nanoparticles for co-delivery of cytarabine and daunorubicin in leukemia.
    Heydari SR; Ghahremani MH; Atyabi F; Bafkary R; Jaafari MR; Dinarvand R
    Int J Pharm; 2023 Nov; 646():123495. PubMed ID: 37806507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release.
    Hu X; Wang Y; Peng B
    Chem Asian J; 2014 Jan; 9(1):319-27. PubMed ID: 24115568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fabrication of Chitosan-coated Mesoporous Silica Nanoparticles Bearing Rosuvastatin as a Drug Delivery System.
    Ghahfarokhi MR; Dini G; Movahedi B
    Curr Drug Deliv; 2022; 19(1):64-73. PubMed ID: 34151762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy.
    Lohiya G; Katti DS
    Carbohydr Polym; 2022 Feb; 277():118822. PubMed ID: 34893239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chitosan-glucuronic acid conjugate coated mesoporous silica nanoparticles: A smart pH-responsive and receptor-targeted system for colorectal cancer therapy.
    Narayan R; Gadag S; Cheruku SP; Raichur AM; Day CM; Garg S; Manandhar S; Pai KSR; Suresh A; Mehta CH; Nayak Y; Kumar N; Nayak UY
    Carbohydr Polym; 2021 Jun; 261():117893. PubMed ID: 33766378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells.
    Hanafi-Bojd MY; Moosavian Kalat SA; Taghdisi SM; Ansari L; Abnous K; Malaekeh-Nikouei B
    Drug Dev Ind Pharm; 2018 Jan; 44(1):13-18. PubMed ID: 28832225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polydopamine-based surface modification of mesoporous silica nanoparticles as pH-sensitive drug delivery vehicles for cancer therapy.
    Chang D; Gao Y; Wang L; Liu G; Chen Y; Wang T; Tao W; Mei L; Huang L; Zeng X
    J Colloid Interface Sci; 2016 Feb; 463():279-87. PubMed ID: 26550786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facile Synthesis of Three Types of Mesoporous Silica Microspheres as Drug Delivery Carriers and their Sustained-Release Properties.
    Zhu Y; Wang B; Chen J; He J; Qiu X
    Curr Drug Deliv; 2023; 20(9):1337-1350. PubMed ID: 35713141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pH-Sensitive Nanosystem Based on Carboxymethyl Chitosan for Tumor-Targeted Delivery of Daunorubicin.
    Zhang X; Zhang H; Yin L; Hu R; Qiu T; Yin Y; Xiong X; Zheng H; Wang Q
    J Biomed Nanotechnol; 2016 Aug; 12(8):1688-98. PubMed ID: 29342347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thermo- and pH-responsive targeted lipid-coated mesoporous nano silica platform for dual delivery of paclitaxel and gemcitabine to overcome HER2-positive breast cancer.
    Nasri N; Saharkhiz S; Dini G; Yousefnia S
    Int J Pharm; 2023 Dec; 648():123606. PubMed ID: 37972671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
    Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
    Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboxyl-functionalized mesoporous silica nanoparticles for the controlled delivery of poorly water-soluble non-steroidal anti-inflammatory drugs.
    Gou K; Wang Y; Guo X; Wang Y; Bian Y; Zhao H; Guo Y; Pang Y; Xie L; Li S; Li H
    Acta Biomater; 2021 Oct; 134():576-592. PubMed ID: 34280558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
    Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
    Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
    Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
    J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pH-dependent release.
    Shahein SA; Aboul-Enein AM; Higazy IM; Abou-Elella F; Lojkowski W; Ahmed ER; Mousa SA; AbouAitah K
    Int J Nanomedicine; 2019; 14():5503-5526. PubMed ID: 31410001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery.
    Quan G; Pan X; Wang Z; Wu Q; Li G; Dian L; Chen B; Wu C
    J Nanobiotechnology; 2015 Feb; 13():7. PubMed ID: 25643602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of curcumin by a pH-responsive chitosan mesoporous silica nanoparticles for cancer treatment.
    Ahmadi Nasab N; Hassani Kumleh H; Beygzadeh M; Teimourian S; Kazemzad M
    Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):75-81. PubMed ID: 28278578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
    Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
    Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sterically Stabilised Polymeric Mesoporous Silica Nanoparticles Improve Doxorubicin Efficiency: Tailored Cancer Therapy.
    Moodley T; Singh M
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32046364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan.
    Biswas N
    Eur J Pharm Sci; 2017 Mar; 99():152-160. PubMed ID: 27993684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.